On August 11, 2020 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, reported that CEO, John M. Climaco, will be issuing a shareholder webinar on August 13th, 2020 at 4:30pm ET to discuss business developments and the progress of the Company’s lead candidate Berubicin, novel DNA-binding agent WP1244 and development agreement with WPD Pharmaceuticals for WP1122 (Press release, CNS Pharmaceuticals, AUG 11, 2020, View Source [SID1234563463]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the webinar are below:
Date:
August 13th, 2020
Time:
4:30-5:00pm ET
Link: